📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Modi Naturals Credit Rating Upgraded to IVR BBB/Stable for Rs 65 Crore Bank Facilities
Infomerics Valuation and Ratings has upgraded the credit ratings for Modi Naturals Limited's bank facilities totaling Rs. 65.00 crore. The long-term rating has been revised upward to IVR BBB with a Stable outlook, while the short-term rating has been upgraded to IVR A3+. This upgrade is based on the company's improved operational and financial performance during FY25 and the first nine months of FY26. The rated facilities include a Rs. 55 crore Cash Credit and a Rs. 10 crore Letter of Credit/Bank Guarantee.
Key Highlights
Long-term rating upgraded to IVR BBB/Stable for Rs. 55.00 crore Cash Credit facility
Short-term rating upgraded to IVR A3+ for Rs. 10.00 crore non-fund based facilities
Total bank loan facilities reviewed and rated amount to Rs. 65.00 crore
Rating revision reflects positive financial performance evaluation for FY25 and 9MFY26
💼 Action for Investors
Investors should view this credit upgrade as a positive indicator of the company's improving financial health and reduced credit risk. This could potentially lead to lower borrowing costs and better access to capital in the future.
Loading analysis...
Modi Naturals to Close Pilibhit Unit and Sell Machinery for ₹63 Lakhs
Modi Naturals Limited has announced the closure of its manufacturing unit in Pilibhit, Uttar Pradesh, citing operational non-viability. The unit contributed approximately ₹16 crores (4%) to the company's standalone turnover and ₹90 lakhs (0.81%) to its net worth in the last financial year. The company is selling the plant and machinery for ₹63 lakhs while retaining the land and building assets. Management expects no material adverse impact as production will be absorbed by another nearby facility with spare capacity.
Key Highlights
Closure of Pilibhit manufacturing unit due to non-viability of operations
Unit contributed ₹16 crores (4% of standalone turnover) and ₹90 lakhs (0.81% of net worth)
Plant and machinery sold for ₹63 lakhs to a non-promoter buyer; land and building retained
Production volumes to be absorbed by a nearby solvent extraction plant with adequate spare capacity
Transaction expected to be completed by April 23, 2026
💼 Action for Investors
This is a strategic consolidation move to eliminate a non-viable unit with minimal impact on overall revenue. Investors should monitor if the consolidation leads to improved margins in the bulk oil segment.
Loading analysis...
Modi Naturals Doubles Ethanol Capacity to 282 KLPD at Chhattisgarh Plant
Modi Naturals' wholly-owned subsidiary, Modi Biotech Private Limited, has commenced commercial operations at its expanded grain-based ethanol plant in Chhattisgarh. The facility's capacity has been significantly increased from 130 KLPD to 282 KLPD, representing a 117% expansion in production capability. This strategic move aligns with the Government of India's Ethanol Blended Petrol (EBP) Programme, positioning the company to benefit from rising biofuel demand. The expansion is expected to enhance operational efficiencies and contribute meaningfully to the company's revenue growth in the coming quarters.
Key Highlights
Ethanol production capacity enhanced from 130 KLPD to 282 KLPD
Commencement of commercial operations at the expanded facility of subsidiary Modi Biotech Private Limited
Strategic alignment with the Government of India's Ethanol Blended Petrol (EBP) Programme
Expected to drive higher production volumes and improve overall operational efficiencies
💼 Action for Investors
Investors should view this as a major growth milestone that significantly scales the company's high-margin ethanol business. Monitor the upcoming quarterly results for the impact of this capacity ramp-up on the company's profitability and revenue mix.
Loading analysis...
Modi Naturals Q3 PAT Jumps 28.5% YoY; FY26 Revenue Guidance Revised Downward
Modi Naturals reported a strong 28.5% YoY growth in Q3FY26 PAT to ₹10.0 crore, despite a 2.8% dip in consolidated revenue to ₹174.1 crore. For the 9MFY26 period, PAT rose 33.9% to ₹30.6 crore, driven by improved operating leverage and lower finance costs from debt repayment. However, the company has lowered its FY26 revenue guidance to ₹720-730 crore from ₹850-880 crore due to delays in commissioning its 180 KLPD ethanol expansion. The ethanol division remains the primary growth catalyst, with total capacity set to reach 310 KLPD by the end of February 2026.
Key Highlights
Q3FY26 PAT increased by 28.5% YoY to ₹10.0 crore, while EBITDA grew 20.7% to ₹16.0 crore.
9MFY26 EBITDA margins expanded to 10.3% from 8.4% YoY, aided by softer raw material costs and lower finance charges.
Ethanol capacity expansion of 180 KLPD is scheduled for commissioning by late February 2026, taking total capacity to 310 KLPD.
FY26 revenue guidance slashed to ₹720-730 crore (previously ₹850-880 crore) due to ethanol project delays.
Consumer division revenue stood at ₹46.3 crore in Q3, showing resilience despite GST-related billing disruptions in October 2025.
💼 Action for Investors
Investors should monitor the successful commissioning and ramp-up of the 180 KLPD ethanol facility in Q4, as this is critical for meeting revised targets. While the guidance cut is a short-term negative, the improving margin profile and debt reduction are positive indicators for long-term stability.
Loading analysis...
Modi Naturals Q3 Net Profit Rises 28% YoY to ₹10.04 Cr Despite Marginal Revenue Dip
Modi Naturals reported a consolidated net profit of ₹10.04 crore for the quarter ended December 31, 2025, representing a 28.5% growth compared to ₹7.82 crore in the previous year. While revenue from operations saw a slight decline of 2.7% YoY to ₹174.09 crore, the company significantly improved its bottom line through reduced finance costs and strong subsidiary performance. For the nine-month period, PAT surged by 33.9% to ₹30.61 crore. The subsidiary, Modi Biotech Private Limited, played a crucial role, contributing ₹81.19 crore to the quarterly revenue and ₹8.92 crore to the profit.
Key Highlights
Consolidated Net Profit increased to ₹10.04 crore in Q3 FY26 from ₹7.82 crore in Q3 FY25.
Revenue from operations stood at ₹174.09 crore, down slightly from ₹179.02 crore YoY.
Finance costs decreased significantly to ₹1.82 crore from ₹3.14 crore in the year-ago quarter.
Subsidiary Modi Biotech Private Limited contributed ₹81.19 crore in revenue and ₹8.92 crore in PAT for the quarter.
Nine-month PAT grew to ₹30.61 crore compared to ₹22.86 crore in the corresponding period last year.
💼 Action for Investors
Investors should note the strong profitability growth driven by the biotech subsidiary and efficient cost management. The reduction in finance costs suggests improving financial health, making it a stock to watch for further margin expansion.
Loading analysis...
Modi Naturals Q3 FY26 Consolidated PAT Rises 28.5% YoY to ₹10.04 Cr; Revenue at ₹174.09 Cr
Modi Naturals reported a strong bottom-line performance for the quarter ended December 31, 2025, with consolidated Net Profit rising to ₹10.04 crore from ₹7.82 crore in the same period last year. While revenue from operations saw a marginal decline to ₹174.09 crore compared to ₹179.02 crore YoY, the company's profitability improved significantly. The nine-month performance also showed robust growth, with PAT reaching ₹30.61 crore against ₹22.86 crore in the previous year. The subsidiary, Modi Biotech, played a crucial role, contributing nearly 47% of the group's quarterly revenue.
Key Highlights
Consolidated Net Profit for Q3 FY26 increased by 28.5% YoY to ₹1,004.43 lakhs.
Revenue from operations for the quarter stood at ₹17,409.31 lakhs, slightly down from ₹17,901.68 lakhs in Q3 FY25.
Nine-month (9M FY26) PAT grew by 33.9% to ₹3,061.00 lakhs compared to ₹2,286.49 lakhs in 9M FY25.
Subsidiary Modi Biotech Private Limited contributed ₹8,118.71 lakhs in revenue and ₹892.05 lakhs in PAT during the quarter.
Earnings Per Share (EPS) for the quarter improved to ₹7.55 from ₹5.88 in the corresponding previous year quarter.
💼 Action for Investors
Investors should focus on the company's improving margins and the strong contribution from its biotech subsidiary which is driving profitability. The stock may see positive momentum due to the significant jump in net profit despite stagnant revenue growth.